About: Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro
Creator	Chen, R Sun, J Xiao, Z Zhang, Y Zhao, Y Shi, J Wu, T Zhou, X Fang, W Shi, X Fan, P Gong, S Jiang, L Research Pan, Antiviral Shang, X
topic	covid:18c7340382aefdae419f2dbe5dbb04df6215a7c4#this
Source	Elsevier; Medline; PMC
abstract	COVID-19, which is caused by the emerging human coronavirus SARS-CoV-2, has become a global pandemic that poses a serious threat to human health. To date, no vaccines or specific antiviral drugs have been approved for the treatment of this disease in clinic. Herein, therapeutic antibodies for SARS-CoV-2 were obtained from hyperimmune equine plasma. First, a recombinant SARS-CoV-2 spike protein receptor-binding domain (RBD) was obtained in gram-level quantities through high-cell density fermentation of Chinese hamster ovary cells. Then, the binding of the RBD to the SARS-CoV-2 receptor, human angiotensin-converting enzyme 2, was verified by several biochemical methods. The efficacy of the RBD in triggering antibody response in vivo was subsequently tested in both mice and equines, and the results showed that the RBD triggered high-titer neutralizing antibody production in vivo. Immunoglobulin F(ab’)(2) fragments were prepared from equine antisera via removal of the Fc region from the immunoglobulins. Finally, a neutralization test with live virus demonstrated that RBD-specific F(ab’)(2) inhibited SARS-CoV-2 with an EC(50) of 0.07 μg/ml and an EC(80) of 0.18 μg/ml, showing a potent inhibitory effect on SARS-CoV-2. These results highlight RBD-specific equine immunoglobulin F(ab’)(2) fragment as a candidate for the treatment of SARS-CoV-2.
has issue date	2020-07-10(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2020.104868
bibo:pmid	32659292
has license	no-cc
sha1sum (hex)	18c7340382aefdae419f2dbe5dbb04df6215a7c4
schema:url	https://doi.org/10.1016/j.antiviral.2020.104868
resource representing a document's title	Immunoglobulin fragment F(ab’)(2) against RBD potently neutralizes SARS-CoV-2 in vitro
has PubMed Central identifier	PMC7351055
has PubMed identifier	32659292
schema:publication	Antiviral Res
resource representing a document's body	covid:18c7340382aefdae419f2dbe5dbb04df6215a7c4#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/18c7340382aefdae419f2dbe5dbb04df6215a7c4
is schema:about of	named entity 'Fc region' named entity 'inhibited' named entity 'poses' named entity 'RBD' named entity 'Immunoglobulin' named entity 'inhibitory' named entity 'QUANTITIES' named entity 'REMOVAL' named entity 'FRAGMENTS' named entity 'PREPARED' named entity '0.07' named entity 'CANDIDATE' named entity 'EQUINE' named entity 'HIGH' named entity 'IN VIVO' named entity 'DATE' named entity 'candidate' named entity 'production' named entity 'antibodies' named entity 'emerging' named entity 'response' named entity 'prepared' named entity 'caused' named entity 'removal' named entity 'vaccines' named entity 'antibody' named entity 'fermentation' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'mice' named entity 'virus' named entity 'Immunoglobulin' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'RBD' named entity 'plasma' named entity 'RBD' named entity 'biochemical' named entity 'immunoglobulin' named entity 'RBD' named entity 'RBD' named entity 'triggered' named entity 'assay' named entity '3,3',5,5'-tetramethylbenzidine' named entity 'Laboratory Animal' named entity 'Fc regions' named entity 'SARS-CoV-2' named entity 'protein' named entity 'protein' named entity 'thrombin' named entity 'immunizations' named entity 'Dulbecco's modified Eagle's medium' named entity 'antigenicity' named entity 'RBD' named entity 'Chinese Academy of Sciences' named entity 'antibody response' named entity 'murine' named entity 'intramuscular injection' named entity 'antibody response' named entity 'plasma collection' named entity 'immunoglobulins' named entity 'Chinese Academy of Sciences' named entity 'rhesus monkeys' named entity 'PBS' named entity 'virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software